About the Vaccine
One of the Recommended Vaccines by Disease
Two vaccines containing measles, mumps, and rubella virus are licensed for use in the United States.
- M-M-R II® is a combination measles, mumps, and rubella (MMR) vaccine.
- ProQuad® is a combination measles, mumps, rubella, and varicella (MMRV) vaccine.
Both vaccines contain live, attenuated measles, mumps, and rubella virus. MMRV also contains live, attenuated varicella-zoster virus. All vaccine strains, including the Moraten strain (used in the United States) and the Edmonston- Zagreb strain are in genotype A.
The lyophilized live MMR vaccine and MMRV vaccine should be reconstituted and administered as recommended by the manufacturer1,2.
- Merck & Co. Inc. M-M-R II (Measles, mumps, and rubella virus vaccine live); 2009.
- Merck & Co. Inc. ProQuad (measles, mumps, rubella and varicella virus vaccine live lyophilized preparation for subcutaneous injection). 2011.
- 1 dose of MMR vaccine is—
- 93% effective for measles (range: 39%–100%)
- 78% effective for mumps (range: 49%−92%)
- 97% effective for rubella (range: 94%–100%)
- 2 doses of MMR are—
- 97% effective for measles (range: 67%–100%)
- 88% effective for mumps (range: 31%–95%)
Duration of Protection
People who receive MMR vaccination according to the U.S. vaccination schedule are considered protected for life.
- Both serologic and epidemiologic evidence indicate that vaccine-induced measles immunity appears to be long-term and probably lifelong in most persons.
- Studies indicate that one dose of vaccine confers long-term, probably lifelong, protection against rubella.
- Studies indicate that 1 dose of MMR vaccine can provide persistent antibodies to mumps.
The United States’ long-standing vaccine safety program closely and constantly monitors the safety of vaccines. See in-depth information about the safety of each FDA-approved vaccine:
- Page last reviewed: November 22, 2016
- Page last updated: February 2, 2018
- Content source: